JENEFFER AVALOS TOPETE: Open Payments
NPI 1952062689 · O FALLON, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$509 in 26 payments from 12 companies in 2025. Trend: 2023 $18 · 2024 $746 · 2025 $509
Food & beverage: $509
| Company | Payments | Amount |
|---|---|---|
| ARS Pharmaceuticals Operations, Inc. | 5 | $109 |
| GENZYME CORPORATION | 4 | $99 |
| Genentech USA, Inc. | 3 | $61 |
| AstraZeneca Pharmaceuticals LP | 3 | $52 |
| CSL Behring | 2 | $41 |
| GlaxoSmithKline, LLC. | 2 | $36 |
| Optinose US, Inc. | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Cycle Pharmaceuticals Inc | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
Products named: DUPIXENT, NEFFY, Xolair, Andembry, FASENRA, NUCALA, Xhance, Sajazir.
Industry payments across MO — which companies pay providers there.
